• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用携带肿瘤抑制性微小RNA的胰蛋白酶处理的细胞外囊泡同时靶向肿瘤细胞和肿瘤相关巨噬细胞以重编程胶质母细胞瘤

Simultaneous Targeting of Tumor Cells and Tumor-Associated Macrophages To Reprogram Glioblastoma Using Trypsinized Extracellular Vesicles Carrying Tumor Suppressive MicroRNA.

作者信息

Nguyen Grace H, Noh MinHye, Kang Jin Muk, Miller Alexandra A, Huang Minxin, Kim Jiyeon, Lee Jeong-Yeon, Chung Sangwoon, Wang Hongyu, Calin George A, Ju Cynthia, Eltzschig Holger K, Banasavadi-Siddegowda Yeshavanth, Zhao Zhongming, Yoo Ji Young, Lee Tae Jin

机构信息

Department of Neurosurgery, McGovern Medical School, University of Texas Health Science Center at Houston, 6431 Fannin Street, Houston, Texas 77030, United States.

Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center-UT Health at Houston, 6767 Bertner Avenue, Houston, Texas 77030, United States.

出版信息

Nano Lett. 2025 May 21;25(20):8414-8422. doi: 10.1021/acs.nanolett.5c01897. Epub 2025 May 13.

DOI:10.1021/acs.nanolett.5c01897
PMID:40357748
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12398074/
Abstract

Glioblastoma (GBM) remains difficult to treat due to poor drug delivery across the blood-brain barrier and an immunosuppressive tumor microenvironment (TME). Tumor-suppressive microRNAs (miRNAs) offer a promising strategy to reprogram both tumor cells and the TME, but inefficient delivery systems limit their clinical application. We previously reported that tumor-suppressive miR-138 regresses tumor growth in preclinical GBM models. Here, we demonstrate that trypsin digestion of extracellular vesicles (EVs) enhances labeling efficiency with folate (FA), enhancing selective targeting of folate receptor (FR)-positive GBM cells and enabling simultaneous targeting of tumor-associated macrophages (TAMs). FA-labeled trypsinized EVs (tEVs) loaded with miR-138 inhibit tumor growth, depolarize TAMs, and enhance antitumor immunity. This study represents the first preclinical attempt to modulate tumor cells and innate immunity via miRNA-loaded tEVs, offering a novel and more effective therapeutic approach to GBM treatment.

摘要

由于药物难以穿过血脑屏障以及免疫抑制性肿瘤微环境(TME),胶质母细胞瘤(GBM)仍然难以治疗。肿瘤抑制性微小RNA(miRNA)为重新编程肿瘤细胞和TME提供了一种有前景的策略,但低效的递送系统限制了它们的临床应用。我们之前报道过,肿瘤抑制性miR-138在临床前GBM模型中可使肿瘤生长消退。在此,我们证明对细胞外囊泡(EV)进行胰蛋白酶消化可提高叶酸(FA)标记效率,增强对叶酸受体(FR)阳性GBM细胞的选择性靶向,并能够同时靶向肿瘤相关巨噬细胞(TAM)。装载有miR-138的FA标记胰蛋白酶处理的EV(tEV)可抑制肿瘤生长,使TAM去极化,并增强抗肿瘤免疫力。本研究是首次通过装载miRNA的tEV调节肿瘤细胞和先天免疫的临床前尝试,为GBM治疗提供了一种新颖且更有效的治疗方法。

相似文献

1
Simultaneous Targeting of Tumor Cells and Tumor-Associated Macrophages To Reprogram Glioblastoma Using Trypsinized Extracellular Vesicles Carrying Tumor Suppressive MicroRNA.利用携带肿瘤抑制性微小RNA的胰蛋白酶处理的细胞外囊泡同时靶向肿瘤细胞和肿瘤相关巨噬细胞以重编程胶质母细胞瘤
Nano Lett. 2025 May 21;25(20):8414-8422. doi: 10.1021/acs.nanolett.5c01897. Epub 2025 May 13.
2
Blocking ITGA5 potentiates the efficacy of anti-PD-1 therapy on glioblastoma by remodeling tumor-associated macrophages.阻断整合素α5(ITGA5)可通过重塑肿瘤相关巨噬细胞增强抗程序性死亡蛋白1(PD-1)疗法对胶质母细胞瘤的疗效。
Cancer Commun (Lond). 2025 Mar 14. doi: 10.1002/cac2.70016.
3
Reprogramming Tumor-Associated Macrophage by Ornithine Decarboxylase Inhibitor and Immune Checkpoint for Orthotopic Glioblastoma Photothermal Immunotherapy.鸟氨酸脱羧酶抑制剂和免疫检查点重编程肿瘤相关巨噬细胞用于原位胶质母细胞瘤光热免疫治疗
ACS Appl Mater Interfaces. 2025 Jun 18;17(24):35155-35167. doi: 10.1021/acsami.5c04588. Epub 2025 Jun 3.
4
Chemoradiation-Altered Micromilieu of Glioblastoma Cells Particularly Impacts M1-like Macrophage Activation.放化疗改变的胶质母细胞瘤细胞微环境对M1样巨噬细胞活化有显著影响。
Int J Mol Sci. 2025 Jul 8;26(14):6574. doi: 10.3390/ijms26146574.
5
Targeting MS4A4A: A novel pathway to improve immunotherapy responses in glioblastoma.针对 MS4A4A:改善胶质母细胞瘤免疫治疗反应的新途径。
CNS Neurosci Ther. 2024 Jul;30(7):e14791. doi: 10.1111/cns.14791.
6
Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM.检查点抗体受体修饰的武装CAR T细胞可规避胶质母细胞瘤中的抑制性免疫组。
Front Immunol. 2025 Jul 31;16:1579925. doi: 10.3389/fimmu.2025.1579925. eCollection 2025.
7
Noninvasive Activation of Local and Systemic Immunity with a Sequential-Targeting Sonodynamic Nanovaccine to Treat Glioblastoma.用序贯靶向声动力纳米疫苗无创激活局部和全身免疫治疗胶质母细胞瘤
ACS Nano. 2025 Aug 5;19(30):27804-27824. doi: 10.1021/acsnano.5c08928. Epub 2025 Jul 23.
8
Virtual Clinical Trial Reveals Significant Clinical Potential of Targeting Tumor-Associated Macrophages and Microglia to Treat Glioblastoma.虚拟临床试验揭示了靶向肿瘤相关巨噬细胞和小胶质细胞治疗胶质母细胞瘤的巨大临床潜力。
CPT Pharmacometrics Syst Pharmacol. 2025 Jul;14(7):1156-1167. doi: 10.1002/psp4.70033. Epub 2025 May 9.
9
Targeting autophagy and plasminogen activator inhibitor-1 increases survival and remodels the tumor microenvironment in glioblastoma.靶向自噬和纤溶酶原激活物抑制剂-1可提高胶质母细胞瘤的生存率并重塑肿瘤微环境。
J Exp Clin Cancer Res. 2025 Jul 19;44(1):214. doi: 10.1186/s13046-025-03473-w.
10
Glioblastoma-associated macrophages in glioblastoma: from their function and mechanism to therapeutic advances.胶质母细胞瘤中的胶质母细胞瘤相关巨噬细胞:从其功能、机制到治疗进展
Cancer Gene Ther. 2025 Apr 30. doi: 10.1038/s41417-025-00905-9.

本文引用的文献

1
Harnessing exosomes for targeted drug delivery systems to combat brain cancer.利用外泌体构建靶向给药系统以对抗脑癌。
Cancer Cell Int. 2025 Apr 15;25(1):150. doi: 10.1186/s12935-025-03731-z.
2
Targeting of Extracellular Vesicle-Based Therapeutics to the Brain.基于细胞外囊泡的疗法对大脑的靶向作用。
Cells. 2025 Apr 4;14(7):548. doi: 10.3390/cells14070548.
3
Targeting delivery of miR-146a via IMTP modified milk exosomes exerted cardioprotective effects by inhibiting NF-κB signaling pathway after myocardial ischemia-reperfusion injury.通过 IMTP 修饰的牛奶外泌体靶向递送 miR-146a,通过抑制心肌缺血再灌注损伤后的 NF-κB 信号通路发挥心脏保护作用。
J Nanobiotechnology. 2024 Jul 1;22(1):382. doi: 10.1186/s12951-024-02631-0.
4
Therapeutically harnessing extracellular vesicles.治疗性利用细胞外囊泡。
Nat Rev Drug Discov. 2022 May;21(5):379-399. doi: 10.1038/s41573-022-00410-w. Epub 2022 Mar 2.
5
MicroRNA-138 Increases Chemo-Sensitivity of Glioblastoma through Downregulation of Survivin.微小RNA-138通过下调生存素增加胶质母细胞瘤的化疗敏感性。
Biomedicines. 2021 Jul 6;9(7):780. doi: 10.3390/biomedicines9070780.
6
Extracellular vesicles as a next-generation drug delivery platform.细胞外囊泡作为下一代药物递送平台。
Nat Nanotechnol. 2021 Jul;16(7):748-759. doi: 10.1038/s41565-021-00931-2. Epub 2021 Jul 1.
7
MicroRNA-138 suppresses glioblastoma proliferation through downregulation of CD44.微小 RNA-138 通过下调 CD44 抑制脑胶质瘤增殖。
Sci Rep. 2021 Apr 28;11(1):9219. doi: 10.1038/s41598-021-88615-8.
8
Bioorthogonally surface-edited extracellular vesicles based on metabolic glycoengineering for CD44-mediated targeting of inflammatory diseases.基于代谢糖基工程的生物正交表面编辑细胞外囊泡用于 CD44 介导的炎症性疾病靶向治疗。
J Extracell Vesicles. 2021 Mar;10(5):e12077. doi: 10.1002/jev2.12077. Epub 2021 Mar 12.
9
The Risks of miRNA Therapeutics: In a Drug Target Perspective.miRNA 治疗的风险:从药物靶点角度看。
Drug Des Devel Ther. 2021 Feb 22;15:721-733. doi: 10.2147/DDDT.S288859. eCollection 2021.
10
Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs.叶酸受体β鉴定出具有免疫抑制作用的肿瘤相关髓系细胞,这些细胞可以用叶酸靶向药物重新编程。
Cancer Res. 2021 Feb 1;81(3):671-684. doi: 10.1158/0008-5472.CAN-20-1414. Epub 2020 Nov 17.